Skip to main content

Table 1 Patient and tumour characteristics and 5-year overall survival

From: Log odds of positive lymph nodes is prognostically equivalent to lymph node ratio in non-metastatic colon cancer

Variable   N (%) 5-year OS (95% CI) p-value
N (1st episode)   n = 856   
Sex Male 402 (47.0) 82 (73.5, 91.5) 0.4
Female 454 (53.0) 86 (80.2, 92.2)  
Age at first surgery < 60 146 (17.1) 91.5 (82.9, 100) < 0.001
60–79 424 (49.5) 91.3 (87.1, 95.7)  
≥ 80 286 (33.4) 65.4 (51.1, 83.7)  
N (All episodes)   n = 862   
Tumour site Caecum 143 (16.6) 77.4 (67.4, 89) < 0.001
Ascending colon 172 (20.0) 69 (51.4, 92.6)  
Hepatic flexure 61 (7.1) 92.4 (82.8, 100)  
Transverse colon 130 (15.1) 83 (72.9, 94.6)  
Splenic flexure 43 (5.0) n/a  
Descending colon 33 (3.8) n/a  
Sigmoid colon 217 (25.2) 98.9 (97.3, 100)  
Rectosigmoid 63 (7.3) 82.8 (68.6, 100)  
T stage 0–2 327 (37.9) 93.3 (88.9, 97.9) < 0.001
3 451 (52.3) 80.4 (71.5, 90.4)  
4 84 (9.7) n/a  
N stage 0 619 (71.8) 85.2 (79, 91.9) 0.01
1 165 (19.1) 85.3 (74.2, 98.1)  
2 78 (9.0) 71.2 (57.4, 88.4)  
ASA 1 151 (17.5) 95.9 (90.0, 100) < 0.001
2 348 (40.4) 91.0 (86.6, 95.7)  
3 315 (36.5) 73.7 (60.2, 90.3)  
4 47 (5.5) 46.1 (28.9, 73.6)  
Pathological grade Undifferentiated 5 (0.6) n/a 0.009
Poor differentiation 164 (19.0) 74.7 (64.5, 86.6)  
Moderate differentiation 579 (67.2) 85.3 (78.1, 93)  
Well differentiated 47 (5.5) 91.7 (77.3, 100)  
LVI No 591 (68.6) 84.9 (78.5, 91.8) 0.02
Yes 244 (28.3) 81.7 (74.6, 89.4)  
CRM Negative > 1 mm 465 (53.9) 79.6 (69.3, 91.4) 0.4
Positive ≤1 mm 8 (0.9) n/a  
Not reported 375 (43.5) 86.6 (81.8, 91.6)  
LNY <12 168 (19.5) 85.4 (78.6, 92.9) 0.5
≥12 694 (80.5) 83.4 (76.7, 90.6)  
LNR groups < 0.05 655 (76.0) 85.8 (79.8, 92.3) < 0.001
0.05 to < 0.2 128 (14.8) 90.7 (82.8, 99.4)  
≥0.2 78 (9.0) 61.3 (45.3, 82.9)  
LODDS <−1.36 569 (66.0) 84.5 (77.6, 92.1) < 0.001
−1.36 to −0.53 217 (25.2) 91.0 (85.7, 96.6)  
> − 0.53 75 (8.7) 61.1 (44.9, 83.2)  
  1. ASA American Society of Anesthesiologists, CI Confidence interval, CRM Circumferential margin, LNR Lymph node ratio, LNY Lymph node yield, LODDS Log odds of positive lymph nodes, LVI Lymphovascular invasion, OS Overall survival.
\